טוען...
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential
Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway, and ther...
שמור ב:
| הוצא לאור ב: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5349426/ https://ncbi.nlm.nih.gov/pubmed/28344663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016683905 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|